Neumora Therapeutics, Inc.

Contributing Author

Recent Articles by Neumora Therapeutics, Inc.

Feb-04	Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 NMRA GlobeNewswire
Jan-05	Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones NMRA GlobeNewswire
Jan-05	Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation NMRA GlobeNewswire
Nov-06	Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Nov-03	Neumora Therapeutics to Participate in Upcoming Conferences in November NMRA GlobeNewswire
Oct-27	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 NMRA GlobeNewswire
Oct-27	Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model NMRA GlobeNewswire
Oct-01	Neumora Therapeutics to Host Virtual R&D Day on October 27 NMRA GlobeNewswire
Sep-02	Neumora Therapeutics to Participate in Upcoming Conferences in September NMRA GlobeNewswire
Aug-06	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Jul-23	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 NMRA GlobeNewswire
Jul-09	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 NMRA +13.12% GlobeNewswire
May-12	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.